Harbour reports results from HCC combo therapy trial

Harbour reports results from HCC combo therapy trial

Source: 
Clinical Trials Arena
snippet: 

Harbour BioMed has reported results from a Phase Ib clinical trial of porustobart (HBM4003) combined with toripalimab for the treatment of hepatocellular carcinoma (HCC).